News and Press Releases


Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) Test, a Powerful Biomarker for Inflammation and its Role in Major Cardiac Events (2/22/2017) - Download Press Release Link to Press Release on Yahoo CLEVELAND, Feb. 22, 2017 /PRNewswire/ — Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of more »
Cleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an Important Measure of Gut Dysfunction that is Associated with Cardiovascular Disease Risk (2/16/2016) - Download Press Release Link to Press Release on Yahoo Innovative new test published in The New England Journal of Medicine detects levels of TMAO – which, when elevated, correlates with a two-fold increased risk of heart attack or stroke February 16, 2016, CLEVELAND: Cleveland HeartLab Inc., the premier cardiovascular disease management company, announced it has successfully developed, validated and launched a new more »
Cleveland HeartLab Partnering with Procter & Gamble and Cleveland Clinic to Advance Discovery in Heart Disease with TMAO Testing (8/19/2015) - Link to Press Release Corporate Communications 9500 Euclid Ave. / JJN4-01 Cleveland, OH 44195 Phone: 216.444.0141 Fax: 216.445.3040 clevelandclinic.org/newsroom   Contacts: Cleveland Clinic: Robert Smith, 216.385.6179, smithr5@ccf.org P&G: Michelle Vaeth, 513-622-4727, vaeth.m@pg.com Cleveland HeartLab: Bethany Hilt, 330-338-6633, bethany.hilt@gmail.com   CLEVELAND CLINIC PARTNERING WITH PROCTER & GAMBLE AND CLEVELAND HEARTLAB TO ADVANCE DISCOVERY IN HEART DISEASE The Partners Will Build Upon more »
CHL Receives Internationally Recognized Quality Designation ISO 13485 and Achieves CE Mark (5/19/2015) - Cleveland HeartLab Receives Internationally Recognized Quality Designation ISO 13485 and Achieves CE Mark for New Universal CardioMPO Assay; Opening New Global Markets for Valuable and Proprietary MPO Testing Recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, the new Universal CardioMPO test will now enable clinicians globally to utilize this important test for patient care CLEVELAND, more »
Journal of Medical Economics – CHL testing could reduce events by 10%, saving $187 Million (4/21/2015) - Link to Press Release New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease—The Number One Killer of Men and Women in the U.S The American Heart Association estimates 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol. Cleveland HeartLab’s inflammation more »
CHL Reiterates Support of Cholesterol Guidelines (9/22/2014) - Dear Colleagues, Upon completion of our 5th Annual symposium, “Where Inflammation Meets Lipids”, I believe it is an opportune time for a comment regarding our thoughts on the ACC/AHA National Cholesterol Guidelines. At this symposium we had a lively and detailed discussion/debate on the new guidelines and we are grateful to all that participated. We at Cleveland HeartLab support the more »
Cleveland HeartLab Tests can save $180 Million in Healthcare Costs, As discussed on Yahoo Health: (6/2/2014) - Cleveland HeartLab Presents Research Demonstrating its Prognostic Tests can save $180 Million in Healthcare costs related to Cardiovascular Disease, the Number One killer of Men and Women in the US Read the Story on Yahoo Health: http://health.yahoo.net/experts/dayinhealth/simple-tests-heart-attack-risk-could-save-lives-and-180-million First-of-its-kind economic model to be presented today at the International Society of PharmacoEconomics and Outcomes Research (ISPOR) conference validates enormous cost savings from more »
Clinical Experts and Entrepreneurs to Converge on Cleveland to Discuss Broad-Based Strategies for Reducing Chronic Disease (2/25/2014) - Cleveland HeartLab announces highlight speakers for its Fifth Annual Symposium, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention.” CLEVELAND, February 25, 2014 – Cleveland HeartLab Inc., a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its Fifth Annual Symposium titled, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention,” will focus on more »
Inflammation Testing Proving Valuable Predictor of Cardiac Risk for Corporate Wellness Programs (2/5/2014) - Cleveland HeartLab CEO to present findings at Health & Wellness Congress CLEVELAND, OH (Feb. 5, 2014) – Leading companies are increasingly recognizing that traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart more »
Groundbreaking new study on Dysfunctional HDL published in Nature Medicine. Technology exclusively licensed to CHL. (1/28/2014) - Yahoo Health discusses Study: HDL, the “Good” Cholesterol Can Be Bad for Your Heart. Published January 27, 2014. HDL — the so-called “good” cholesterol—sometimes goes rogue and clogs arteries instead of keeping them healthy, according to a groundbreaking new study published in Nature Medicine. …“These are great discoveries,” said Jake Orville, CEO of Cleveland HeartLab (CHL), which has licensed this test more »
ICD-10 Code Update (8/7/2015) - As you know, the healthcare industry went through a major change with the implementation of ICD-10 codes on October 1, 2015.  We want to ensure you that we are ICD-10 ready and are currently prepared to receive and process ICD-10 codes.
International Conference on Nutrition in Medicine (2/20/2015) - The International Conference on Nutrition in Medicine will be held in Washington, D.C. , July 31st and August 1st, 2015. CHL is pleased to be an educational sponsor for the International Conference on Nutrition in Medicine, where Dr. Marc Penn will be speaking on “Laboratory tests: Which Ones Do I Need and Not Need?” Come join us and make sure more »
CHL Reiterates Support of Cholesterol Guidelines (9/22/2014) - Dear Colleagues, Upon completion of our 5th Annual symposium, “Where Inflammation Meets Lipids”, I believe it is an opportune time for a comment regarding our thoughts on the ACC/AHA National Cholesterol Guidelines. At this symposium we had a lively and detailed discussion/debate on the new guidelines and we are grateful to all that participated. We at Cleveland HeartLab support the more »
Cleveland HeartLab makes National News: Cleveland – Booming in more ways than Lebron (8/11/2014) - NEW YORK (CNNMoney) “Down the street from Jake Orville’s office in downtown Cleveland, you can hear the cutting of steel gears from a nearly 100-year-old manufacturer of machinery parts. Just beyond that lies Millionaire’s Row, a stretch of historic homes built by industrial tycoons like John Rockefeller and Western Union founder Jeptha Wade, who dominated the city in the late more »
Cleveland HeartLab Receives Crystal Award for Excellence from Ohio’s Edison Technology Centers (3/27/2014) - CLEVELAND, March 27, 2014 – Jake Orville, CEO of Cleveland HeartLab, accepted today the Crystal Award for Excellence from Ohio’s Edison Technology Centers. The presentation was made by its Edison Centers Director Council during a luncheon held at the Ohio statehouse and attended by state legislators and executives from other innovative companies. The six Edison Technology Centers located in Ohio more »
Groundbreaking new study on Dysfunctional HDL published in Nature Medicine. Technology exclusively licensed to CHL. (1/28/2014) - Yahoo Health discusses Study: HDL, the “Good” Cholesterol Can Be Bad for Your Heart. Published January 27, 2014. HDL — the so-called “good” cholesterol—sometimes goes rogue and clogs arteries instead of keeping them healthy, according to a groundbreaking new study published in Nature Medicine. …“These are great discoveries,” said Jake Orville, CEO of Cleveland HeartLab (CHL), which has licensed this test more »
Yahoo Health discusses the value of Cleveland HeartLab testing. (1/10/2014) - …reported recently, the multi-marker approach identified 37 to 43 percent more at-risk patients than would have been found using levels of LDL (bad) cholesterol alone, scientists from Cleveland HeartLab and MDVIP found. This combination testing approach helped stratify which patients were at highest risk for a heart attack, according to lead study author Marc Penn, MD, PhD, chief medical officer of Cleveland HeartLab. more »
Marc Penn, 2013 Symposium, Trials and Tribulations of Assessing CVD Risk in 2013 (11/11/2013) - Marc Penn, MD, PhD, FACC discusses the Trials and Tribulations of Assessing CVD Risk in 2013 at the 2013 Cleveland HeartLab Symposium in Dallas, Texas. Listen as Dr. Marc Penn reviews strategies for defining cardiovascular risk based on novel biomarker tests.  To open, Dr. Penn reviews recent literature that supports the lowering of hsCRP to reduce cardiovascular risk and initial more »
Interview with Marc Penn, MD, PhD, FACC (10/30/2013) - Dr. Marc Penn discusses the importance and impact that inflammation testing can have in your practice, providing a more complete picture of an individual’s risk for heart disease.
Video Highlights from TEDMED (6/27/2013) - Cleveland HeartLab’s Chief Medical Officer, Marc Penn, MD, PhD discusses results of TEDMED attendees who got inflammation testing or “IT” during this year’s conference, held at the Kennedy Center in Washington, DC.
CHL on Memphis Channel 3 (5/26/2013) - Watch Cleveland HeartLab CEO Jake Orville being interviewed by WREG Memphis Channel 3 about the importance of inflammation testing on their morning Live at Nine program.
Know Your Risk Video™ from Cleveland HeartLab (4/30/2013) - Watch the Know Your Risk Video™ from Cleveland HeartLab  to learn about the link between heart disease and inflammation. Hear how practitioners learn which patients are at high risk and from patients who have been tested. Patients can take action to reduce their risk of heart attacks and strokes. Yet heart disease kills one American every 34 seconds. It’s still the leading more »
Cleveland HeartLab to bring “it” to 2013 County Radio Seminar (2/15/2013) - CLEVELAND HEARTLAB ON TOUR IN NASHVILLE TO BRING EXCLUSIVE – ‘IT’ – INFLAMMATION TESTING TO ATTENDEES AT THE 2013 COUNTRY RADIO SEMINAR CHL to Provide Inflammation Testing at CRS as Part of American Heart Month CLEVELAND, Feb. 13, 2012 – Cleveland HeartLab (CHL), an advanced clinical laboratory focused on heart inflammation testing, is going on the road to provide the more »
CHL in Worth Magazine (11/26/2012) - CHL Inflammation Panel Featured in Worth Magazine Cleveland HeartLab’s Chief Medical Officer, Marc Penn, MD, PhD was featured in the August issue of Worth Magazine talking about the benefits of our Inflammation Panel as a predictor for heart disease and events.
Revitalizing Downtown Cleveland (10/16/2012) - For decades, much of Northeast Ohio’s growth migrated to the suburbs…new buildings, office parks, factories. But one local company has reversed that trend and is creating jobs and hope in downtown Cleveland. Like many others, Fred Geis’s family came to Northeast Ohio for a brighter future. He and his brother built a flourishing development company…then turned their attention from suburban more »
Cleveland’s Biomedical Business Boom (7/18/2012) - Cleveland’s WKYC featured Cleveland HeartLab in this recent news story about the growing biomedical business boom taking place in the region.
Biomarker Test Firm Cleveland HeartLab Eyes Health and Wellness Market (7/18/2012) - After making major inroads among community-based physicians, cardiac inflammation biomarker test company Cleveland HeartLab is looking to expand its business into the health and wellness market. The Cleveland-based clinical reference laboratory, which provides cardiovascular testing for thousands of U.S. physicians, is now aiming to partner with health and wellness companies and self-insured employers to diversify its customer base, CEO Jake more »
MicrOHscope Story on “it” (7/18/2012) - A story from MicrOHscope: Ohio’s Bioscience Blog and News Source – Cleveland HeartLab Wants Everyone to Know What “it” Is Cleveland HeartLab (CHL) chose the TEDMED Conference in D.C. last week to kick-off a campaign to educate patients and health care professionals about the importance of “it,” or inflammation testing, in determining heart attack and stroke risk. [Read More at more »
How is Cleveland HeartLab helping to transform Cleveland? (7/18/2012) - Watch this video to see how Cleveland HeartLab is helping to transform Cleveland’s MidTown neighborhood, located between downtown and University Circle.
Cleveland HeartLab Named Venture of the Year (5/3/2012) - Cardiac inflammation biomarker test company Cleveland HeartLab has been tapped as the Ohio Venture Association‘s ” venture of the year.” The last year has been an eventful one for the Cleveland-based company: It spurned a buyout offer from an unidentified Massachusetts suitor, closed an $18.4 million series B round of investment, moved into a new building that quadrupled its office more »
Cleveland HeartLab adds three key executives (9/28/2011) - Cleveland HeartLab Inc., a company developing proprietary heart disease tests, has added three executives to its management team. Deborah H. Sun, Ph.D., has been appointed vice president of laboratory operations. Cleveland HeartLab said Dr. Sun has more than 20 years of experience in the field of clinical laboratory management. She most recently was scientific director of clinical pathology at South more »
Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) Test, a Powerful Biomarker for Inflammation and its Role in Major Cardiac Events (2/22/2017) - Download Press Release Link to Press Release on Yahoo CLEVELAND, Feb. 22, 2017 /PRNewswire/ — Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of more »
Cleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an Important Measure of Gut Dysfunction that is Associated with Cardiovascular Disease Risk (2/16/2016) - Download Press Release Link to Press Release on Yahoo Innovative new test published in The New England Journal of Medicine detects levels of TMAO – which, when elevated, correlates with a two-fold increased risk of heart attack or stroke February 16, 2016, CLEVELAND: Cleveland HeartLab Inc., the premier cardiovascular disease management company, announced it has successfully developed, validated and launched a new more »
Cleveland HeartLab Partnering with Procter & Gamble and Cleveland Clinic to Advance Discovery in Heart Disease with TMAO Testing (8/19/2015) - Link to Press Release Corporate Communications 9500 Euclid Ave. / JJN4-01 Cleveland, OH 44195 Phone: 216.444.0141 Fax: 216.445.3040 clevelandclinic.org/newsroom   Contacts: Cleveland Clinic: Robert Smith, 216.385.6179, smithr5@ccf.org P&G: Michelle Vaeth, 513-622-4727, vaeth.m@pg.com Cleveland HeartLab: Bethany Hilt, 330-338-6633, bethany.hilt@gmail.com   CLEVELAND CLINIC PARTNERING WITH PROCTER & GAMBLE AND CLEVELAND HEARTLAB TO ADVANCE DISCOVERY IN HEART DISEASE The Partners Will Build Upon more »
CHL Receives Internationally Recognized Quality Designation ISO 13485 and Achieves CE Mark (5/19/2015) - Cleveland HeartLab Receives Internationally Recognized Quality Designation ISO 13485 and Achieves CE Mark for New Universal CardioMPO Assay; Opening New Global Markets for Valuable and Proprietary MPO Testing Recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, the new Universal CardioMPO test will now enable clinicians globally to utilize this important test for patient care CLEVELAND, more »
Journal of Medical Economics – CHL testing could reduce events by 10%, saving $187 Million (4/21/2015) - Link to Press Release New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease—The Number One Killer of Men and Women in the U.S The American Heart Association estimates 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol. Cleveland HeartLab’s inflammation more »
Nutrasource Diagnostics Inc. Announces the Availability of the OmegaCheck™ Omega-3 Blood Test through Cleveland HeartLab (3/13/2015) - Link to PRWeb Press Release Guelph, Ontario, Canada (February 23, 2015) Nutrasource Diagnostics Inc. (NDI) is pleased to announce its recent collaboration with Cleveland HeartLab (CHL) for the development of the OmegaCheck™ diagnostic blood test for the quantification of omega fatty acids. As a global leader in launching proprietary tests to more accurately assess cardiovascular disease risk, CHL developed and more »
CHL Launches New Medical Education Program (3/9/2015) - Link to PRWeb Press Release World-class, accredited continuing medical education (CME) now available as one-stop source for information on the identification and prevention of metabolic and cardiovascular disease CLEVELAND, March 9, 2015 – Cleveland HeartLab (CHL), the premier cardiovascular management company, announces the launch of its new CME Web Portal, Continuing Education from Cleveland HeartLab. The website (www.chlcme.com ) will more »
Cleveland HeartLab Tests can save $180 Million in Healthcare Costs, As discussed on Yahoo Health: (6/2/2014) - Cleveland HeartLab Presents Research Demonstrating its Prognostic Tests can save $180 Million in Healthcare costs related to Cardiovascular Disease, the Number One killer of Men and Women in the US Read the Story on Yahoo Health: http://health.yahoo.net/experts/dayinhealth/simple-tests-heart-attack-risk-could-save-lives-and-180-million First-of-its-kind economic model to be presented today at the International Society of PharmacoEconomics and Outcomes Research (ISPOR) conference validates enormous cost savings from more »
Clinical Experts and Entrepreneurs to Converge on Cleveland to Discuss Broad-Based Strategies for Reducing Chronic Disease (2/25/2014) - Cleveland HeartLab announces highlight speakers for its Fifth Annual Symposium, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention.” CLEVELAND, February 25, 2014 – Cleveland HeartLab Inc., a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its Fifth Annual Symposium titled, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention,” will focus on more »
Inflammation Testing Proving Valuable Predictor of Cardiac Risk for Corporate Wellness Programs (2/5/2014) - Cleveland HeartLab CEO to present findings at Health & Wellness Congress CLEVELAND, OH (Feb. 5, 2014) – Leading companies are increasingly recognizing that traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart more »
Fine-Tuning the Investment in Employee Health (8/23/2013) - CLEVELAND – August 2013 – When Classic Auto Group launched its car shopping website, they said they were bringing the showroom direct to the customer. This month, Classic Auto Group is launching a new employee health program based on the same principle: bringing health care directly to their employees. Despite spending over $100,000 on the program, president Jim Brown knows from experience that it won’t more »
Report Confirms Multimarker Approach as Definitive Tool (8/15/2013) - Report Confirms Multimarker Approach as Definitive Tool to Identify and Help Diminish Cardiovascular Risk –Cleveland HeartLab and MDVIP Co-Authored, Peer-Reviewed Article Analyzing Biomarker Test Data from 95,000 Patients– (July 18, 2013, Boca Raton, FL & Cleveland, OH) – A just-published report, co-authored by the medical leadership of Cleveland HeartLab (CHL) and MDVIP for the peer-reviewed journal Future Cardiology (July 2013), clearly more »
Oswald Companies Announces Partnership with Cleveland HeartLab (8/13/2013) - Oswald Companies, one of the largest independently owned insurance brokerage and consulting firms in the U.S., is proud to offer its clients the next generation of health screenings through a strategic partnership with Cleveland HeartLab, Inc.
Cleveland HeartLab announces speakers for its 4th annual symposium (3/28/2013) - Cleveland HeartLab announces speakers for its 4th annual symposium on cardiovascular disease, preventive medicine 12 CME credits approved for this industry-leading event CLEVELAND, Aug. 28, 2013 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its fourth annual symposium, Where Inflammation Meets Lipids®, will focus on unique models and strategies for more »
CHL Honored with Prestigious 2013 NorTech Innovation Award (3/18/2013) - CLEVELAND, March 15, 2013 – Cleveland HeartLab announced today that the company was recognized as a recipient of the 2013 NorTech Innovation Awards. The award was received yesterday by Cleveland HeartLab, President and CEO, Jake Orville at the annual awards ceremony in Independence, Ohio. Cleveland HeartLab was recognized for its work in the field of applied biosciences for leadership in more »
Cleveland HeartLab announces $14.7 million financing (10/22/2012) - Contacts: Jake Orville President & Chief Executive, Cleveland HeartLab Inc. 216-426-6081 Jason Lansdale Marketing Manager, Cleveland HeartLab Inc. 216-426-6081, ext. 1450 Rod Hise The Luminis Group, Ltd. for Cleveland HeartLab Inc. 608-770-7850 For Immediate Release Cleveland HeartLab closes $14.7-million financing CLEVELAND, Oct. 22, 2012 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today more »
Cleveland HeartLab New Leadership 2012 (8/7/2012) - Contacts: Jake Orville President & Chief Executive, Cleveland HeartLab Inc. 216-426-6081 Jason Lansdale Marketing Manager, Cleveland HeartLab Inc. 216-426-6081, ext. 1450 Rod Hise The Luminis Group, Ltd. for Cleveland HeartLab Inc. 608-770-7850 For Immediate Release Cleveland HeartLab expands scientific, sales leadership teams with appointment of three key executives CLEVELAND, Aug. 7, 2012 – Cleveland HeartLab Inc. (CHL), a rapidly growing more »
CHL Launches “it” inflammation testing Campaign (4/11/2012) - Cleveland HeartLab Launches “it” Campaign to Raise Awareness of Inflammation Testing April 11, 2012 09:03 AM Eastern Daylight Time CLEVELAND — Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced the launch of a campaign to educate patients and health care professionals about the importance of “it,” or inflammation testing, in determining more »